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Abstract 
Polycystic Ovarian Syndrome (PCOS) is the leading cause of anovulatory infertility and the most 
common endocrinopathy in women of reproductive age (Rosenfield & Ehrmann, 2016).  It has 
been recognized that women with PCOS often struggle with infertility and require medication to 
stimulate ovulation to become pregnant. Currently, the first-line treatment for infertility 
associated with PCOS is clomiphene citrate, which was introduced in the 1960s (Morad & Farag, 
2015). However, it has been proposed that an aromatase inhibitor, specifically letrozole, should 
become the first-line treatment for these patients due to a decreased adverse effect profile, a 
lower incidence of simultaneous multiple gestation pregnancies, and a decreased risk of 
congenital abnormalities. The purpose of this study is to determine if letrozole is an equal or 
better alternative to clomiphene citrate for infertility treatment in PCOS patients. An extensive 
literature review was performed, and letrozole was found to have higher ovulation rates, fewer 
twin pregnancies/more single births, higher pregnancy rates, and higher live birth rates compared 
to clomiphene citrate. There were conflicting results for endometrial thickness and single follicle 
stimulation. Neither letrozole or clomiphene citrate was superior to the other for ovarian 
hyperstimulation syndrome. There were no significant differences between letrozole and 
clomiphene citrate regarding congenital abnormalities and miscarriage rates. The results 
regarding ectopic pregnancies were comparable between both groups. In conclusion, the results 
provide information supporting letrozole as an adequate first-line alternative to clomiphene 
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Infertility in Polycystic Ovarian Syndrome 
Polycystic Ovarian Syndrome (PCOS) is the leading cause of anovulatory infertility and 
the most common endocrinopathy in women of reproductive age (Rosenfield & Ehrmann, 2016).  
It has been recognized that women with PCOS often struggle with infertility and require 
medication to stimulate ovulation to become pregnant. Currently, the first-line treatment for 
infertility associated with PCOS is clomiphene citrate, which was introduced in the 1960s 
(Morad & Farag, 2015). In addition, 25% of patients with infertility are clomiphene citrate 
resistant and unable to ovulate, and many are unable to conceive with clomiphene citrate and 
subsequently experience clomiphene citrate failure (Legro et al., 2014). Clomiphene citrate has 
also been associated with a limited efficacy including a 22% live birth rate and increased risk of 
multiple pregnancies (Legro et al., 2014).  
It has been discussed that an aromatase inhibitor, specifically letrozole, should become 
the first-line treatment for these patients due to a decreased adverse effect profile, a lower 
incidence of simultaneous multiple gestation pregnancies, increased endometrial thickness better 
promoting pregnancy, and a decreased risk of cardiac congenital abnormalities. 
Statement of the Problem 
Clomiphene citrate has been the first-line treatment for infertility in patients with PCOS 
for quite some time. If an alternative to clomiphene citrate is available that is safer, more 
efficacious and bears less adverse effects, it should be implemented as the first-line treatment in 
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Research Questions 
In the patient with polycystic ovarian syndrome, is letrozole compared to clomiphene 
citrate more effective for ovulation induction, endometrial thickness, single follicle 
stimulation/single gestation birth, pregnancy rate, and live birth rate? 
In the patient with polycystic ovarian syndrome, is letrozole compared to clomiphene 
citrate safer for the mother and baby regarding ovarian hyperstimulation syndrome, congenital 
anomalies, ectopic pregnancies, and miscarriage rates? 
If letrozole is found to be more effective and safe, this could have a tremendous impact 
on healthcare for PCOS patients struggling with infertility. Today, some women may feel 
defeated with current treatment options. The possibility that letrozole may improve outcomes for 
these women and their families is very promising. 
Review of Literature 
Online database searches were performed for the literature review using PubMed, 
Cochrane Library, and ClinicalKey. The searches included terms related to infertility in patients 
with PCOS such as letrozole, clomiphene citrate, Femara, Clomid, infertility, PCOS, safety of 
letrozole, safety of clomiphene citrate, among many others. The information used to produce this 
scholarly project includes information from within the last five years, except for one article 
referenced from 2011 due to historical information regarding the medication. The population 
used for all studies in the literature review were adult women of childbearing age diagnosed with 
polycystic ovarian syndrome. All significant findings in the studies are defined as having a p-
value <0.05. Studies that didn't specifically relate to PCOS patients were excluded.  
  The literature review is divided into four sections to guide the reader beginning with the 
pathophysiology of PCOS and its effects on infertility. The second section of the literature 
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review discusses the current treatment options for patients with PCOS struggling with infertility. 
The remaining two sections of the literature review focus on comparing the efficacy and safety 
of letrozole compared to clomiphene citrate.  
The Pathophysiology of Polycystic Ovarian Syndrome and Its Effects on Infertility  
Normal physiology. A condensed review of physiology related to natural ovulation will 
be discussed. First, the ovary's functional unit is known as a follicle. Within the follicle is an 
oocyte, or the immature egg, which is surrounded by granulosa cells and theca cells. In the non-
PCOS woman, the hypothalamus is appropriately stimulated to release gonadotropin-releasing 
hormone (GnRH), which acts on the anterior pituitary gland in the brain to release follicle 
stimulating hormone (FSH) and luteinizing hormone (LH). LH works on the theca cells of the 
ovary to produce androgens, while FSH works on the granulosa cells of the ovary to convert 
these androgens into estradiol. Once converted, this large amount of estradiol stimulates the 
brain to release more LH, known as the LH surge, which stimulates the dominant follicle to grow 
and eventually release the egg into the fallopian tube for implantation in the uterus. This process 
is known as ovulation (Reed & Carr, 2015).  
Pathophysiology of PCOS. According to Dumesic, Oberfield, Stener-Victorin, Marshall, 
and Laven (2016), PCOS is an endocrinopathy in which the cause isn't well understood. 
However, it is known that it consistently produces a plethora of metabolic complications 
including menstrual irregularities and increased levels of androgens. This occurs in response to 
abnormal circulation of sex steroids, insulin activity, and distinct ovarian characteristics. It is 
thought that obesity exacerbates these complications and they can vary in severity depending on 
ethnicity and race (Dumesic et al., 2016). 
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Androgen excess. According to Rosenfield and Ehrmann (2016), there is strong evidence 
to support the hypothesis that the excess androgen production that occurs in PCOS is a result of a 
defect in the theca cells of the ovary. Specifically, studies have shown that the theca cells in 
PCOS patients have a higher number of cytochrome P450c17 enzymes and a higher number of 
proteins known as DENND1A that are used in steroidogenesis. The exact purpose of DENND1A 
in steroidogenesis is unknown, however there is discussion that it may facilitate up-regulation in 
signaling the LH receptors. Furthermore, there are increased numbers of LH receptors in the 
PCOS patient (Rosenfield & Ehrmann, 2016). Rosenfield and Ehrmann (2016) also discuss that 
dysregulation of the zona reticularis within the adrenal cortex may be another factor contributing 
to excess androgens in PCOS patients, as the normal steroidogenesis process of the zona 
reticularis is altered and results in increased androgen production (Rosenfield & Ehrmann, 2016).  
It is believed that there is increased ovarian sensitivity to LH in the patient with PCOS, 
thus increasing LH secretion and causing an overabundance of LH. The excess insulin as 
previously discussed has been identified as a cause of this hypersensitivity, as excess insulin 
sensitizes the ovary to LH. However, LH excess is only present in half of PCOS patients. The 
increased LH compared to FSH results in more androgens, since fewer androgens are being 
converted to estradiol (Rosenfield & Ehrmann, 2016). 
Metabolic syndrome and insulin resistance. Close to half of patients with PCOS have 
insulin-resistant hyperinsulinism (Rosenfield & Ehrmann, 2016). Rosenfield and Ehrmann 
(2016) state that "insulin resistance in PCOS is characterized by reduced sensitivity and 
responsiveness to insulin-mediated glucose utilization primarily in skeletal muscle and adipose 
tissue, although the nature of these defect differs," (Rosenfield & Ehrmann, 2016). The over-
release of insulin is thought to be due to a compensatory response to the insulin resistance, which 
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also promotes increased androgen levels. Type II diabetes mellitus may occur if pancreatic beta 
cells begin to fail due to the increased insulin secretion from insulin resistance (Rosenfield & 
Ehrmann, 2016).  
Etiologies. Rosenfield and Ehrmann (2016) discuss that both environmental and genetic 
factors trigger PCOS. Genetic factors that can contribute to PCOS include high levels of 
androgens, insulin resistance, and altered insulin secretion, while environmental effects may be 
due to impaired fetal growth, exposure to androgens in vitro, and obesity (Rosenfield & 
Ehrmann, 2016).  
Current Treatment Options for Infertility in Patients with Polycystic Ovarian 
Syndrome 
First-line treatments. In obese women with PCOS, lifestyle changes are strongly 
recommended to achieve a weight loss of 5-10% which may successfully induce ovulation 
without the need for pharmacological therapy (Melo, Ferriani, & Navarro, 2015). Clomiphene 
citrate is currently the recommended first-line pharmacological treatment for ovulation induction 
in patients with PCOS. The usual dose and duration of clomiphene citrate is 50 mg per day for 
five days, but it may be increased by 50 mg up to a maximum of 150 mg for five days if there is 
no ovulation or development of follicles (Legro, 2016).  In patients resistant to clomiphene 
citrate, metformin may be added as an adjunct medication which may improve pregnancy rates; 
the addition of metformin is still considered first-line treatment if the patient is resistant to 
clomiphene citrate alone (Melo et al., 2015).  
Clomiphene citrate was first approved for ovulation induction in the 1960s. It belongs to 
the pharmacological category referred to as nonsteroidal selective estrogen receptor modulators 
(SERMs).  It works by binding to the estrogen receptors as it has a very similar structure to 
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estrogen. This decreases the ability for true estrogen to bind to estrogen receptors, which 
produces an antiestrogenic effect. In response, the pituitary gland releases more FSH since it 
appears that the estrogen level is low, which in turn stimulates the ovaries to ovulate (Morad & 
Farag, 2015). 
Letrozole is currently being debated as either an equal or better alternative to clomiphene 
citrate due to the reasons discussed earlier in this project. Its most significant historical use in the 
healthcare field has been for FDA-approved treatment of postmenopausal breast cancer, however 
utilizing it for infertility is currently an off-label use. The usual dose and duration of letrozole is 
2.5 mg per day for five days, however if no ovulation or development of follicles occur it may be 
increased by 2.5 mg up to a maximum dose of 7.5 mg for five days (Legro, 2016). Legro (2016) 
states that "based on current meta-analyses …women with PCOS are about 50% more likely to 
have a live birth with letrozole compared to clomiphene," (Legro, 2016).  
Letrozole works on a different pathway and is categorized as a nonsteroidal aromatase 
inhibitor, meaning that it inhibits the enzyme that converts testosterone and androstenedione into 
various forms of estrogen. Inhibiting this conversion also results in less estrogen binding to the 
estrogen receptors in the brain, thus stimulating FSH to be released from the brain and inducing 
ovulation (Morad & Farag, 2015). 
Second and third-line treatments. Second-line treatment options include injectable 
gonadotropins that aim to induce ovulation, however this method has a higher rate of multiple 
gestation pregnancies and is much costlier than clomiphene citrate and/or clomiphene citrate and 
metformin combined; another second-line treatment option includes laparoscopic ovarian drilling 
(LOD) in patients resistant to clomiphene citrate. Of course, since this option requires surgery, it 
is much costlier as well as has increased risks and should only be performed if surgery is 
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necessary for another obstetrical or gynecological reason. Both methods may result in ovarian 
hyperstimulation syndrome (OHSS), as patients with PCOS are more sensitive to this occurring 
(Melo et al., 2015). Lastly, the third-line treatment option for infertility in PCOS patients 
includes in vitro fertilization (IVF). This method is very costly and is typically only used when 
other options have failed (Melo et al., 2015).  
Efficacy of Letrozole versus Clomiphene Citrate to Induce Ovulation and 
Pregnancy Outcomes  
A randomized control trial by Ghahiri, Magharehabed, and Mamourian (2016) aimed to 
compare the efficacy and safety of letrozole and clomiphene citrate on ovulation and pregnancy. 
The study included 101 women with a mean age of 25 years with primary or secondary infertility 
due to PCOS. It was found that 58% of patients treated with letrozole became pregnant and 47% 
of patients treated with clomiphene citrate became pregnant, however this was not statistically 
significant (p=0.23). Thirty patients treated with clomiphene citrate and 36 patients treated with 
letrozole had regular menstrual cycles either during or after treatment, however this also was not 
statistically significant (p=0.21). The ovulation rate was similar between both groups with the 
clomiphene citrate group having a 58.8% ovulation rate and the letrozole group having a 72% 
ovulation rate, however again this was not statistically significant. All patients completed this 
study, but one from each group did not present after treatment so the authors were unable to 
follow those pregnancy outcomes. The study concluded that letrozole is not superior to 
clomiphene citrate, but that they are equally effective (Ghahiri et al., 2016).  
A randomized control trial was conducted by Sharief and Nafee (2015) that compared 
letrozole and clomiphene citrate in 75 patients between the ages of 18 and 36 with PCOS.  All 
patients had been infertile for at least two years and had hirsutism, normal prolactin and FSH 
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levels, and normal thyroid function. All partners were tested for normal semen analysis. The 
authors found that the letrozole group had a statistically significant lower number of mature 
follicles, with the letrozole group having 1.3 +/- 0.31 mature follicles and the clomiphene citrate 
group having 2.4 +/- 1.1 mature follicles (p=0.0001). The study also found that the letrozole 
group had a significantly higher endometrial thickness, with the letrozole group having an 
endometrial thickness in the sagittal plane of 84 +/-1.8 mm and the clomiphene citrate group 
having an endometrial thickness in the sagittal plane of 52 +/- 1.2 mm (p=0.0001). The letrozole 
group also had a significantly higher ovulation rate with the letrozole group having an 82.9% 
ovulation rate and the clomiphene citrate group having a 62.5% ovulation rate (p=0.05). 
However, the pregnancy rates were not significantly different with the letrozole group having a 
pregnancy rate of 28.6% and the clomiphene citrate group having a pregnancy rate of 17.5% 
(p=0.254). The authors concluded that letrozole may be preferred in select groups of patients, but 
that more studies are needed (Sharief & Nafee, 2015). It is important to consider that the study 
had a small sample size in comparison to other studies included in this project. 
Another randomized control trial conducted by Hussain et al. (2013) compared letrozole 
and clomiphene citrate for ovulation rates, pregnancy rates, endometrial thickness, and whether 
the drug induced only a single follicle to ovulate to prevent multiple gestation pregnancies. The 
study consisted of 150 participants aged between 18 and 40 with PCOS. The participants' 
partners all required normal semen analysis. The letrozole group had a 78.7% ovulation rate 
compared to a 53.3% ovulation rate in the clomiphene citrate group (p=0.001, 95% CI [1.16, 
1.88]). The letrozole group had a 25.3% pregnancy rate compared to a 16% in the clomiphene 
citrate group (p=0.221, 95% CI [0.83, 3.03). The letrozole group had 44.6% single follicle 
ovulations compared to 26.7% in the clomiphene citrate group (p=.0270, 95% CI [0.75, 1.99]). 
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The letrozole group had a 9.2 mm endometrial thickness with a standard deviation of 2.3 mm 
compared to the clomiphene citrate group having an endometrial thickness of 8.4 mm with a 
standard deviation of 2.2 mm (p=0.031, 95% CI [0.1, 3.2]). The only statistically significant 
difference in this study included the ovulation rate (p=0.001) and endometrial thickness 
(p=0.031), which both favored the letrozole group (Hussain et al., 2013). After controlling for 
variables such as type of infertility, age, duration of infertility, BMI, and baseline FSH and LH 
levels, it was determined that patients who received letrozole were greater than three times more 
likely to ovulate than patients who were treated with clomiphene citrate (p=0.003, 95% CI [1.45, 
6.30). It was also found that BMI played a role in determining successful ovulation, with an 
inverse relationship between BMI and chances of a successful ovulation, however patients with 
various BMI's were distributed similarly in both groups (p=0.004, 95% CI [0.85, 0.97]) (Hussain 
et al., 2013). The study concluded that patients treated with letrozole had statistically significant 
higher ovulation rates and increased endometrial thickness compared to clomiphene citrate 
(Hussain et al., 2013). Lastly, the study found that letrozole was better at stimulating only one 
follicle, unlike clomiphene citrate which had higher rates of multiple follicle stimulation 
resulting in multiple simultaneous gestations (Hussain et al., 2013). Overall, the authors felt that 
letrozole was better than clomiphene citrate for ovulation induction. Limitations of this study 
include that 10% of the participants were over 35 years of age, which is a more difficult 
population to successfully conceive (Hussain et al., 2013).  
A double-blind, randomized trial conducted by Legro et al. (2014) consisted of 750 
women between the ages of 18 and 40 and aimed to determine if letrozole produced better 
pregnancy outcomes than clomiphene citrate. The primary outcome measured in the study was 
live birth, while secondary outcomes included congenital abnormalities, pregnancy loss, 
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ovulation, and multiple simultaneous gestation pregnancies. The study determined that the 
letrozole group had a significantly higher cumulative live birth rate than letrozole, with the 
letrozole group having a cumulative live birth rate of 27.5% compared to 19.1% for the 
clomiphene citrate group (p=0.007, 95% CI [1.10, 1.87]). However, there was not a significant 
difference in the live birth rate "according to treatment cycle," (Legro et al., 2014). The letrozole 
group showed a significantly higher ovulation rate than clomiphene citrate at every visit 
following the initial visit, with the letrozole group having an 88.5% ovulation rate and the 
clomiphene citrate group having an ovulation rate of 76.6% (p <0.001, 95% CI [1.08, 1.24]). 
There was also a significantly greater rate of single pregnancy with the letrozole group compared 
to the clomiphene citrate group, with the letrozole group having a single pregnancy rate of 34.1% 
and the clomiphene citrate group having a single pregnancy rate of 26% (p=0.03, 95% CI [1.03, 
1.58]). The study found that the clomiphene citrate group experienced improvement in patients' 
androgen levels and hirsutism. Letrozole had a greater decrease in anti-Mullerian hormones 
compared to clomiphene citrate but had less of an increase in endometrial thickness when 
compared to clomiphene citrate. However, the authors feel that the results on ovulation and live 
birth rates reflect that improvement in hyperandrogenism might not be needed for successful 
ovulation and live birth. Letrozole also had a significantly lower estradiol level than clomiphene 
citrate when measured. The dropout rate and/or those that were excluded include 22.6% in the 
clomiphene citrate group and 19.5% in the letrozole group. The reasons for these withdrawals 
were statistically insignificant between the two groups, however the authors acknowledged that 
this was a high dropout rate and that could be attributed to participants feeling discouraged and 
leaving to find alternative treatments before the study could be finished (Legro et al., 2014). 
Overall, the authors felt that letrozole was better than clomiphene citrate for ovulation induction 
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in patients with PCOS but that more studies are needed regarding its safety on teratogenic effects 
(Legro et al., 2014). A limitation of this study includes a large percentage of the participants 
being classified as obese, however the authors feel that this is an accurate reflection of many 
patients with PCOS in the U.S. The authors also mention that there were no lifestyle 
interventions required prior to the start of the study which is recommended practice. Lastly, the 
authors feel that more studies are necessary to determine the safety of letrozole (Legro et al., 
2014).  
Liu et al. (2017) conducted a randomized control trial to compare ovulation induction 
between clomiphene citrate alone, clomiphene citrate combined with metformin, letrozole alone, 
or letrozole combined with metformin in 268 patients with PCOS. The study also aimed to 
determine if letrozole could replace the first-line treatment of clomiphene citrate. Ovulation, 
pregnancy, and live birth rates were recorded. The pregnancy rate and live birth rate both favored 
the letrozole group, with a pregnancy rate of 52.1% in the letrozole group and 39.7% in the 
clomiphene citrate group, and a live birth rate of 35.3% in the letrozole group and 26.4% in the 
clomiphene citrate group, however neither of these findings were statistically significant (p>0.5). 
Ovulation rates were studied, however the article combined the letrozole group alone and 
letrozole + metformin therapy together and named it the letrozole treatment group, and did the 
same with the clomiphene citrate group by taking the clomiphene citrate group alone and 
clomiphene citrate + metformin therapy together and naming it the clomiphene citrate treatment 
group, so this may be skewed as it includes metformin in both of the treatment groups. With this 
being said, the ovulation rate was significantly higher in the letrozole treatment group with an 
ovulation rate of 73.3% compared to an ovulation rate of 52.7% in the clomiphene treatment 
group (p<0.001). There were no congenital abnormalities noted in any of the 63 newborns. The 
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study concluded that clomiphene citrate should remain the first-line treatment for infertility in 
patients with PCOS. The authors feel that their results differed in comparison to other studies, 
however they attribute this to the Chinese population included in the study (Liu et al., 2017).  
A double-blind, randomized controlled trial conducted by Amer, Smith, Mahran, Fox, 
and Fakis (2017) aimed to determine if letrozole produced better pregnancy rates than 
clomiphene citrate in women with PCOS. The study consisted of 159 participants who were 
between the ages of 18 and 39 with a BMI of 35 kg/m2 or less. The authors found that there were 
significantly higher pregnancy rates with the letrozole group than the clomiphene citrate group, 
with the letrozole group having a pregnancy rate of 61.2% and the clomiphene citrate group 
having a pregnancy rate of 43% (p=0.022, 95% CI [1.1, 2.0]). Other statistically significant 
findings of the study included a higher rate of pregnancies in the letrozole group for those with a 
BMI of less than 30 kg/m2. The letrozole group also had a higher rate of ovulation and 
pregnancies per cycle than the clomiphene citrate group, with the letrozole group having a 19% 
pregnancy rate per cycle and a 75% ovulation rate per cycle, whereas the clomiphene citrate 
group had an ovulation rate per cycle of 67% and pregnancy rate per cycle of 12% (p=0.045, 
95% CI [0.9, 1.2] for ovulation rate per cycle; p=0.036, 95% CI [1.03, 2.3] for pregnancy rate 
per cycle). The endometrial thickness was significantly higher in the clomiphene citrate group 
with a median endometrial thickness of 9.0 mm compared to 8.4 mm in the letrozole group 
(p=0.002). The authors mentioned that women with a BMI greater than 35 kg/m2 were excluded 
but justified this by discussing that this is standard practice in European studies since these 
patient populations are at increased risks for complications and provide more challenges (Amer 
et al., 2017).  
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Al-Shaikh, Al-Mukhatar, Al-Subaidu, Al-Rubaie, and Al-Khuzaee (2017) conducted a 
prospective clinical trial in Iraq consisting of 85 women diagnosed with PCOS struggling to 
conceive. There were 45 women in the clomiphene citrate group and 40 women in the letrozole 
group. The trial measured follicular amount and size, endometrial thickness, and pregnancy rates. 
The trial did not measure miscarriage rates due to losing contact with the patients, however they 
were informed of a few miscarriages. The trial found no significant difference between follicular 
size, however there was a significant difference between the number of mature follicles which 
was higher in the letrozole group. The mean number of mature follicles that were 17 mm in size 
or greater was 1.42 +/- 0.66 in the letrozole group and 1.15 +/- 0.44 in the clomiphene citrate 
group (p<0.05) (Al-Shaikh et al., 2017). The trial also reported significant differences in the 
endometrial thickness between both groups, with the clomiphene citrate group having a higher 
mean. The mean endometrial thickness in the clomiphene citrate group was 9.62 mm +/- 2.66 
mm, whereas the letrozole group had a mean endometrial thickness of 8.02 mm +/- 1.24 mm 
(p<0.05). The trial reported no significant difference in pregnancy rates per cycle between the 
two groups with clomiphene citrate having a 12.12% pregnancy rate per cycle and letrozole 
having a 9.09% pregnancy rate per cycle (p>0.05) (Al-Shaikh et al., 2017).  
Safety of Mother and Baby – Letrozole Versus Clomiphene Citrate  
There has been discussion regarding congenital abnormalities with letrozole use for 
ovulation induction compared to clomiphene citrate. A study conducted by Novartis 
Pharmaceuticals in Canada was presented to the American Society for Reproductive Medicine in 
2005 that provided information that there was a substantial number of birth defects in babies 
born to mothers that had taken letrozole for ovulation induction. The company sent a global 
notice to all physicians informing them that letrozole was contraindicated in all premenopausal 
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or pregnant women due to the increased risk of birth defects. However, Casper and Mitwally 
(2011) stated that "…this study had several methodologic problems and was never accepted for 
peer-reviewed publication," (Casper & Mitwally, 2011).  
Casper & Mitwally (2011) go on to discuss that shortly after this happened, another study 
was performed with 911 babies that were conceived after either clomiphene citrate or letrozole 
treatment. In this study, it was found that only 2.4% of babies whose mothers were treated with 
letrozole and 4.8% of babies whose mothers were treated with clomiphene citrate had congenital 
malformations or chromosomal abnormalities. However, this was deemed statistically 
insignificant due to the small sample size of the study. The authors also mentioned that the 
Centers for Disease Control later conducted a study called the National Birth Defects Prevention 
Study which confirmed that there is a higher risk of congenital cardiac abnormalities with 
clomiphene citrate compared to letrozole (Casper & Mitwally, 2011).  
A study conducted by Sharma et al. (2014) disclosed that there were 5 out of 201 babies 
(2.5%) with congenital or chromosomal abnormalities whose mothers were treated with letrozole 
for ovulation induction, compared to 10 out of 251 babies (3.9%) whose mothers were treated 
with clomiphene citrate (p<0.648, 95% CI [0.207, 1.829] for overall congenital malformations, 
p<0.907, 95% CI [0.249, 2.407] for structural malformations, p<0.226, 95% CI [0.018, 5.191] 
for chromosomal anomalies). The control group included 5 out of 171 babies with congenital or 
chromosomal abnormalities (Sharma et al., 2014). However, it was concluded that there wasn't a 
significant difference in the rate of congenital or chromosomal abnormalities when natural 
conception was used or if the mothers were treated with letrozole or clomiphene citrate. Sharma 
et al. (2014) disclosed in the study that 47 children were born outside of their institute and thus 
the information regarding anomalies was provided by the parents. Sharma et al. (2014) also 
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discuss that the study is retrospective with a relatively small study group, which may be another 
limitation in their study (Sharma et al., 2014).  
A retrospective cohort study was performed by Tatsumi et al. (2017) to compare 
congenital anomalies and adverse pregnancy or neonatal outcomes in patients with natural 
conception versus ovulation induction with the use of letrozole. The study included 3,136 
women with natural cycles and 792 women who used letrozole to achieve pregnancy. 
Miscarriage rates, ectopic pregnancy rates, stillbirth rates, and live birth rates were measured for 
pregnancy outcomes. Although this study does not compare letrozole and clomiphene citrate, the 
findings regarding letrozole are still relevant to the research studied in this project. The letrozole 
group was found to have a 12.2% miscarriage rate compared to a 26.4% miscarriage rate for 
natural cycle pregnancy (p <0.001, 95% CI [0.30, 0.47]). The ectopic pregnancy rate in the 
letrozole group was 0.13% and 0.7% in the natural cycle pregnancy group (p=0.078, 95% CI 
[0.02-1.23]). The stillbirth rate was 0.37% and 0.38% in the letrozole and natural groups, 
respectively (p=0.920, 95% CI [0.30, 3.83]). The live birth rate was 87.1% and 72.2% in the 
letrozole and natural groups, respectively; it is unknown what the p-value or confidence interval 
is for this outcome as they are not disclosed in the article. Major congenital anomalies including 
cardiovascular, musculoskeletal, and chromosomal anomalies existed in 1.9% and 1.5% in the 
letrozole and natural groups, respectively, however this was disclosed as not significant 
(p=0.869,). The authors of the study concluded that letrozole does not increase the risk of major 
congenital anomalies compared to natural cycle pregnancy. The authors also included that the 
use of letrozole may in fact decrease the chances of miscarriage in fresh-embryo cycles. Tatsumi 
et al. (2017) mentioned in the study that only increased risk for large congenital anomalies 
INFERTILTY IN POLYCYSTIC OVARIAN SYNDROME 20 
 
associated with letrozole were able to be ruled out and that the follow-up period for this study 
was shorter compared to other studies (Tatsumi et al., 2017).  
In the study conducted by Legro et al. (2014), more congenital defects were noted in the 
letrozole group with four in the letrozole group having a congenital defect compared to one in 
the clomiphene citrate group, however this was not significant (p=0.65, 95% CI [0.75, 1.60]) 
(Legro et al., 2014). The authors didn't find any significant difference in pregnancy loss or 
multiple gestation pregnancies between either group. The miscarriage rate was comparable 
between both groups with the letrozole group having a miscarriage rate of 31.8% and the 
clomiphene citrate group having a miscarriage rate of 29.1%, but this was not statistically 
significant (p=0.65). Statistically significant findings included a 3% neonatal death rate and 1.5% 
fetal death rate with clomiphene citrate compared to 1% neonatal death rate and 1% fetal death 
rate with letrozole. The exact p-value for these significant findings was not included in the article 
but was disclosed as significant with a p-value <0.05 (Legro et al., 2014).  
Legro (2016) discusses that the half-life of letrozole is much shorter than clomiphene 
citrate, with a two-day half-life. This may provide reasoning for its discussed effects as it is 
removed from the body more rapidly than clomiphene citrate.  He also explains that the 
congenital birth defect rate of letrozole are comparable to clomiphene citrate with a birth defect 
rate less than 5% in two studies (Legro, 2016).  
The study conducted by Liu et al. (2017) reported no congenital abnormalities in the 63 
newborns in any of the groups (Liu et al., 2017).  
The study conducted by Ghahiri et al. (2016) reported five miscarriages in both the 
letrozole and clomiphene citrate group.  In addition, no cases of ovarian hyperstimulation 
syndrome occurred (Ghahiri et al., 2016).  
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Discussion 
With the efficacy and safety of letrozole compared to clomiphene citrate presented 
through various studies in the literature review, the research will now be evaluated and discussed 
in a holistic approach addressing each of the research questions presented in the introduction.  
Significant findings of the studies included an overall higher ovulation rate, single follicle 
ovulation and single pregnancy rate compared to twin pregnancy rate with letrozole, and either 
no significant difference in pregnancy rate or a higher pregnancy rate with letrozole.  
Significant findings of the studies regarding the safety of the mother and baby include no 
significant difference in congenital abnormalities between the two groups or no congenital 
defects at all; differing results on ectopic pregnancy rates; and either no significant difference in 
miscarriage rates or significant findings favoring letrozole for much lower miscarriage rates.  
In the patient with polycystic ovarian syndrome, is letrozole compared to clomiphene 
citrate more effective for ovulation induction, endometrial thickness, single follicle 
stimulation/single gestation birth, pregnancy rate, and live birth rate? 
Ovulation rates. Ghahiri et al. (2016) and Amer et al. (2017) found that there was no 
statistically significant difference in ovulation rates between letrozole and clomiphene citrate, 
while Sharief and Nafee (2015), Hussain et al. (2013), Legro et al. (2014), and Liu et al. (2017) 
all found that letrozole had statistically significant higher ovulation rates. Amer et al. (2017) 
revealed that there may be limitations in his study due to the exclusion of women with PCOS 
that had a BMI greater than 35 kg/m2 (Amer et al., 2017).  
Endometrial thickness. Sharief and Nafee (2015) and Hussain et al. (2013) found that 
letrozole had significantly higher endometrial thickness than clomiphene citrate group while Al-
Shaikh et al. (2017) found that clomiphene citrate had a significantly higher endometrial 
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thickness than letrozole. Amer et al. (2017) found that there was not a statistically significant 
difference in endometrial thickness between either group, however as mentioned previously, 
Amer's (2017) study may have limitations due to the exclusion of women with PCOS that had a 
BMI greater than 35 kg/m2 (Amer et al., 2017).  
Single follicle stimulation/single gestation birth. Sharief and Nafee (2015) found that 
letrozole had a significantly lower number of mature follicles and Hussain et al. (2013) found 
that letrozole had a higher rate of single follicles than clomiphene, however Hussain et al.'s 
(2013) findings were not significant.  Al-Shaikh et al. (2017) however did report a significant 
difference in the number of mature follicles greater than 17 mm, with letrozole having a higher 
number compared to clomiphene citrate. Al-Shaikh et al. (2017) did however mention in their 
study that the letrozole dose was higher in this study (5 mg) which may have enhanced the 
effects of the drug (Al-Shaikh et al., 2017).  
Ghahiri et al. (2016) reported no twin pregnancies in either group, however Sharief and 
Nafee (2015) reported one twin pregnancy in the clomiphene citrate group and none in the 
letrozole group. Amer et al. (2017) reported no twin pregnancies in the letrozole group but 
disclosed a 12.5% twin birth rate in the clomiphene citrate group, however this was not 
significant (Amer et al., 2017).  Legro (2014) reported a significantly higher single pregnancy 
rate with letrozole group compared to clomiphene citrate group (Legro, 2014).  
Pregnancy rates. Ghahiri et al. (2016), Sharief and Nafee (2015), Hussain et al. (2013) 
Liu et al. (2017), and Al-Shaikh et al. (2017) all found that the pregnancy rates were not 
statistically different between letrozole and clomiphene. However, Legro et al. (2014) and Amer 
et al. (2017) found that there were statistically significant higher pregnancy rates with letrozole 
compared to clomiphene citrate. 
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Live birth rates.  Legro et al. (2014) found letrozole to have a significantly higher live 
birth rate than clomiphene citrate while Liu (2017) did not find any significant difference in live 
birth rate. While Tatsumi (2017) didn't compare letrozole and clomiphene citrate, letrozole was 
found to have a higher live birth rate than natural pregnancies (Tatsumi, 2017).  
In the patient with polycystic ovarian syndrome, is letrozole compared to clomiphene 
citrate safer for the mother and baby regarding ovarian hyperstimulation syndrome, 
congenital anomalies, ectopic pregnancies, and miscarriage rates? 
Ovarian hyperstimulation syndrome (OHSS). Ghahiri et al. (2016) and Hussain et al. 
(2013) both reported no cases of ovarian hyperstimulation syndrome in either group (Ghahiri et 
al., 2016). Other studies did not disclose whether any cases of ovarian hyperstimulation 
syndrome occurred. In this regard, neither letrozole or clomiphene citrate is superior to the other 
for a decreased incidence of OHSS. 
Congenital abnormalities. Sharma et al. (2014) found no significant difference between 
letrozole and clomiphene citrate and birth defects compared to natural conception, however 
Legro et al. (2014) reported a higher rate of congenital abnormalities in the letrozole group 
compared to the clomiphene citrate group, although this was not significant. Both Amer et al. 
(2017) and Liu et al. (2017) reported no congenital abnormalities between either group. Tatsumi 
et al. (2017) found that there was not a significant difference in congenital abnormalities between 
the letrozole group and natural pregnancies. 
Ectopic pregnancies. In the clomiphene citrate groups, Ghahiri et al. (2016) reported an 
ectopic pregnancy rate of 8.3% while Legro et al. (2014) reported a higher rate of 12.5%. In 
addition, Amer et al. (2017) had no reports of ectopic pregnancies in the clomiphene citrate 
group (Amer et al., 2017).  
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In the letrozole groups, Ghahiri et al. (2016) reported the highest ectopic pregnancy rate 
of 10.3% and Legro et al. (2014) reported an ectopic pregnancy rate of 2.6%. Amer et al. (2017) 
reported the lowest ectopic pregnancy rate of 2% (Amer et al., 2017).  
The ectopic pregnancy rates in the clomiphene citrate group ranged from 0.0%-12.5% 
while the ectopic pregnancy rate in the letrozole group ranged from 2% to 10.3%.  When 
comparing letrozole and clomiphene citrate between the three studies, the study with the highest 
percentage of ectopic pregnancies was in the clomiphene citrate group, however another study 
reported no ectopic pregnancies with the clomiphene citrate group.  
Miscarriage rates. Legro et al. (2014) reported the highest miscarriage rate in the 
clomiphene citrate group of 29.1% while Amer et al. (2017) reported the lowest miscarriage rate 
in the clomiphene citrate group of 17.6%. Ghahiri et al. (2016) reported a miscarriage rate of 
25%. None of these values were significant with p values all greater than 0.05. However, 
Tatsumi et al. (2017) reported that the miscarriage rates were significant in his study with 
letrozole having a much lower miscarriage rate compared to natural cycle pregnancies. As 
mentioned previously, Al-Shaikh et al. (2017) was not able to determine a formal miscarriage 
rate but was informed of two miscarriages in the clomiphene citrate group and one in the 
letrozole group (Al-Shaikh et al., 2017).  
In conclusion, letrozole was found to have higher ovulation rates, fewer twin 
pregnancies/more single births, higher pregnancy rates, and higher live birth rates compared to 
clomiphene citrate. There were conflicting results for endometrial thickness and single follicle 
stimulation. Neither letrozole or clomiphene citrate was superior to the other for ovarian 
hyperstimulation syndrome. There were no significant differences between letrozole and 
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clomiphene citrate regarding congenital abnormalities and miscarriage rates. The results 
regarding ectopic pregnancies were comparable between both groups. 
Applicability to Clinical Practice 
  Throughout the research presented and discussed in this project, letrozole was found to 
have an overall positive impact on infertility and either better or debatably better outcomes 
regarding its efficacy. Letrozole was found to have higher ovulation rates, fewer twin 
pregnancies/more single births, higher pregnancy rates, and higher live birth rates compared to 
clomiphene citrate. However, the other parameters and safety of letrozole compared to 
clomiphene citrate were either comparable or not statistically significant.  
The applicability of this research to clinical practice is quite remarkable. For many years 
the first-line treatment of infertility in patients with PCOS has been clomiphene citrate; however, 
with the recent data from the studies discussed in this project, it is apparent that letrozole could 
be at the very least an equal alternative, with more research pointing towards an improvement in 
efficacy with letrozole compared to clomiphene citrate.  
Infertility due to PCOS is a very common complaint and a struggle that is frequently 
brought to the provider's attention. Many women have tried to become pregnant with other 
fertility treatments to no avail or are beginning their infertility treatment journey. It is promising 
that with this research and ongoing research, letrozole will become a first-line pharmacological 
treatment for infertility in PCOS patients. Providers will be able to inform their patients of all 
treatment options available including letrozole and the positive impact it can have on infertility.  
With a lower rate of multiple gestation pregnancies and a higher rate of ovulation, 
pregnancy, and live birth rates, women with infertility will be able to have more hope in their 
dreams of becoming a mother with the most effective medication available to them. This could 
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change the provider's way of practice if the provider is able to offer the patient an alternative 
medication that is superior to the traditional option, and ultimately providing the best outcome 
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